Stockscreener 앱 받기
0.1798
17.49%
-0.0381
시간 외 거래:
.18
0.0002
+0.11%
Palatin Technologies Inc. 주식(PTN)의 최신 뉴스
Palatin Technologies Announces Encouraging Pre-Clinical Data Of PL9588 For Glaucoma Treatment - Nasdaq
Palatin (PTN) Unveils Promising Data for Glaucoma Treatment Candidate PL9588 | PTN Stock News - GuruFocus
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy | PTN Stock News - GuruFocus
Breakthrough Dual-Action Glaucoma Therapy Shows 25% Cell Protection in Trial Data | PTN Stock News - Stock Titan
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease - The Malaysian Reserve
Palatin Announces Breakthrough Symptom Resolution in Updated Ana - GuruFocus
Palatin (PTN) Announces Promising Results for PL9643 in Dry Eye Disease Study | PTN Stock News - GuruFocus
Palatin Reports Positive Results From Responder Analyses Of Phase 3 MELODY-1 Study In DED - Nasdaq
First-Ever Complete Symptom Resolution: Game-Changing Phase 3 Results in $6B Dry Eye Market - Stock Titan
Market Resilience: Palatin Technologies Inc (PTN) Finishes Weak at 0.66, Down -5.41 - DWinneX
The Attractiveness of Investing In Palatin Technologies Inc (PTN) is Growing - knoxdaily.com
Trading Day Triumph: Palatin Technologies Inc (PTN) Ends at 0.21, a -1.24 Surge/Plunge - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Palatin Technologies (NYSE:PTN) Now Covered by StockNews.com - Defense World
NYSE to Commence Delisting Proceedings Against Solo Brands, Inc. (DTC) - Business Wire
A Guide To The Risks Of Investing In Palatin Technologies Inc (PTN) - knoxdaily.com
Palatin Technologies Inc’s Banking’s 100-Day Moving Average at 0.8728: Will the Stock Break Through? - investchronicle.com
StockNews.com Begins Coverage on Palatin Technologies (NYSE:PTN) - Defense World
Palatin’s obesity study shows promise in appetite control By Investing.com - Investing.com Canada
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide - The Malaysian Reserve
Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Palatin Technologies, Novaliq, mc2 therapeutics - The Globe and Mail
Palatin (PTN) Reports Positive Phase 2 Study Results for Obesity Treatment | PTN Stock News - GuruFocus
Palatin’s obesity study shows promise in appetite control - Investing.com Australia
Palatin Reports Positive Appetite Suppression Results From Phase - GuruFocus
Breakthrough Obesity Treatment Shows 71% Appetite Control, Blocks Post-Treatment Weight Rebound - Stock Titan
What Analysts Think About Palatin Technologies Inc (AMEX: PTN)’s Potential Raise - stocksregister.com
Palatin Appeals NYSE American Notice of Delisting - Kilgore News Herald
Palatin Technologies (PTN) Appeals NYSE Delisting Decision | PTN Stock News - GuruFocus
Palatin Appeals NYSE American Notice of Delisting | PTN Stock Ne - GuruFocus
Palatin Appeals NYSE Delisting, Pursues Financing And Partnerships To Regain Compliance - Nasdaq
Palatin contests NYSE American delisting notice By Investing.com - Investing.com South Africa
Palatin contests NYSE American delisting notice - Investing.com
Palatin Appeals NYSE American Notice Of Delisting - marketscreener.com
Palatin Appeals NYSE American Notice of Delisting | PTN Stock News - GuruFocus
Stock Slump: Eyewear Innovator And Tech Firms Face Market Hits - Finimize
Palatin Technologies (PTN) Faces NYSE American Delisting Proceedings - GuruFocus
Palatin (PTN) Faces Delisting Proceedings from NYSE American | P - GuruFocus
Palatin to Present Positive Phase 2b Data for Melanocortin Agoni - GuruFocus
Boom Or Bust: Where Is Palatin Technologies Inc (AMEX: PTN) Stock Headed Next? - Marketing Sentinel
Palatin Technologies faces potential NYSE American delisting By Investing.com - Investing.com Canada
Palatin reports promising kidney disease treatment results By Investing.com - Investing.com South Africa
Palatin Technologies shares fall as it receives NYSE American delisting notice - MSN
Palatin Technologies faces potential NYSE American delisting - Investing.com Australia
Palatin Technologies, Inc. Announces Receipt Of NYSE American Notice Of Delisting And Intention To Appeal - marketscreener.com
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal - PR Newswire
Palatin reports promising kidney disease treatment results - Investing.com Australia
0.39%
3.66%
자본화:
|
볼륨(24시간):